These findings give new insight into the immunomodulatory activities of clinical Mtb strains, which may provide useful information about the key molecules, such as GBP1, that can be targeted for developing host‐directed therapeutics to treat TB and prevent reactivation of LTBI [80]. The gene discussed is GBP1; the disease is tuberculosis.